BioStem Technologies, Inc. (OTCMKTS:BSEM) Sees Large Growth in Short Interest

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 88,600 shares, an increase of 41.1% from the September 15th total of 62,800 shares. Based on an average trading volume of 57,200 shares, the short-interest ratio is presently 1.5 days.

BioStem Technologies Trading Down 2.3 %

Shares of BSEM traded down 0.26 during mid-day trading on Monday, hitting 10.89. 21,900 shares of the company’s stock were exchanged, compared to its average volume of 27,344. BioStem Technologies has a fifty-two week low of 2.26 and a fifty-two week high of 15.50. The business’s 50 day moving average is 10.56 and its two-hundred day moving average is 9.79. The firm has a market capitalization of $177.29 million, a P/E ratio of 27.91 and a beta of 0.05.

BioStem Technologies (OTCMKTS:BSEM) last posted its quarterly earnings data on Monday, August 12th. The company reported 0.30 earnings per share for the quarter, topping analysts’ consensus estimates of 0.12 by 0.18. The company had revenue of 74.49 million for the quarter, compared to analyst estimates of 43.99 million. On average, equities research analysts forecast that BioStem Technologies will post 1.13 earnings per share for the current year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.